GSK (NYSE: GSK) is actively negotiating with the U.S. government to explore options for reducing drug prices. This initiative comes as part of a broader response...
GlaxoSmithKline (GSK) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has extended the review period for its blood cancer therapy, Blenrep. This development...